Long-term survival in patients with germ cell testicular cancer: A population-based competing-risks regression analysis

被引:24
作者
Gandaglia, G. [1 ,2 ]
Becker, A. [1 ,3 ]
Trinh, Q-D [1 ,4 ]
Abdollah, F. [2 ]
Schiffmann, J. [1 ,3 ]
Roghmann, F. [1 ,5 ]
Tian, Z. [1 ]
Montorsi, F. [2 ]
Briganti, A. [2 ]
Karakiewicz, P. I. [1 ,6 ]
Sun, M. [1 ]
机构
[1] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[2] Univ Vita Salute San Raffaele, Urol Res Inst, San Raffaele Res Inst, Dept Urol, I-20132 Milan, Italy
[3] Univ Med Ctr Hamburg Eppendolf, Martiniclin, Hamburg, Germany
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Surg,Div Urol,Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Ruhr Univ Bochum, Dept Urol, Bochum, Germany
[6] Univ Montreal, Ctr Hlth, Dept Urol, Montreal, PQ, Canada
来源
EJSO | 2014年 / 40卷 / 01期
关键词
Testicular germ cell tumor; Secondary malignancy; Long-term survival; Other-cancer mortality; Cancer-specific mortality; FOLLOW-UP; CARDIOVASCULAR-DISEASE; 2ND MALIGNANCIES; 5-YEAR SURVIVORS; MORTALITY; SUSCEPTIBILITY; LEUKEMIA; SEMINOMA; TUMORS;
D O I
10.1016/j.ejso.2013.09.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Backgrounds: Incidence of secondary malignancies and cardiovascular diseases among testicular germ cell tumor (TGCT) survivors is higher compared to the general population. We sought to describe the rates of other-cancer (OCM), non-cancer related (NCRM), and cancer-specific mortality (CSM) among men with TGCT. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database, 31,330 patients with a primary diagnosis of TGCT between 1973 and 2009 were identified. The primary endpoints comprised of 15-year CSM, OCM, and NCRM rates. Survival rates were stratified according to histology (seminoma vs. non-seminoma), median age (<34 vs. >= 34 years old), and disease stage (localized vs. regional vs. distant). Competing-risks Poisson regression methodologies were performed. Results: For seminoma patients, the rates of CSM at 15 years increased with advancing stage (0.4-12.6%; P < 0.001), but varies little with age. In contrast, the rates of OCM (0.4-7.9%) and NCRM (2.9-8.9%) at 15 years increased with advancing stage and age (all P < 0.001). For non-seminoma patients, the 15-year CSM rates increased with advancing stage and age (1.9-24.4%; all P < 0.001). For the same time point, the rates of OCM (0.3-11.4%) and NCRM (2.4-8.0%) also increased with age and stage (all P < 0.001). Conclusions: The risk of dying from secondary malignancies or other causes significantly increases with advancing stage and age at diagnosis among TGCT survivors. Such information can help provide patients and physicians with better screening strategies, follow-up protocols, and mental preparedness for such undesirable effects. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:103 / 112
页数:10
相关论文
共 28 条
[1]   EAU Guidelines on Testicular Cancer: 2011 Update [J].
Albers, Peter ;
Albrecht, Walter ;
Algaba, Ferran ;
Bokemeyer, Carsten ;
Cohn-Cedermark, Gabriella ;
Fizazi, Karim ;
Horwich, Alan ;
Laguna, Maria Pilar .
EUROPEAN UROLOGY, 2011, 60 (02) :304-319
[2]   GENETIC SUSCEPTIBILITY TO RADIOGENIC CANCER IN HUMANS [J].
Allan, James M. .
HEALTH PHYSICS, 2008, 95 (05) :677-686
[3]   Outcomes in stage I testicular seminoma: A population-based study of 9193 patients [J].
Beard, Clair J. ;
Travis, Lois B. ;
Chen, Ming-Hui ;
Arvold, Nils D. ;
Nguyen, Paul L. ;
Martin, Neil E. ;
Kuban, Deborah A. ;
Ng, Andrea K. ;
Hoffman, Karen E. .
CANCER, 2013, 119 (15) :2771-2777
[4]   A proportional hazards model for the subdistribution of a competing risk [J].
Fine, JP ;
Gray, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509
[5]   Increased mortality rates in young and middle-aged patients with malignant germ cell tumours [J].
Fosså, SD ;
Aass, N ;
Harvei, S ;
Tretli, S .
BRITISH JOURNAL OF CANCER, 2004, 90 (03) :607-612
[6]   LONG-TERM FOLLOW-UP OF CARDIOVASCULAR RISK-FACTORS IN PATIENTS GIVEN CHEMOTHERAPY FOR DISSEMINATED NONSEMINOMATOUS TESTICULAR CANCER [J].
GIETEMA, JA ;
SLEIJFER, DT ;
WILLEMSE, PHB ;
KOOPS, HS ;
VANITTERSUM, E ;
VERSCHUREN, WMM ;
KROMHOUT, D ;
SLUITER, WJ ;
MULDER, NH ;
DEVRIES, EGE .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (09) :709-715
[7]   A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].
GRAY, RJ .
ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154
[8]   Long-Term and Late Effects of Germ Cell Testicular Cancer Treatment and Implications for Follow-Up [J].
Haugnes, Hege S. ;
Bosl, George J. ;
Boer, Hink ;
Gietema, Jourik A. ;
Brydoy, Marianne ;
Oldenburg, Jan ;
Dahl, Alv A. ;
Bremnes, Roy M. ;
Fossa, Sophie D. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (30) :3752-3763
[9]   Cardiovascular Risk Factors and Morbidity in Long-Term Survivors of Testicular Cancer: A 20-Year Follow-Up Study [J].
Haugnes, Hege S. ;
Wethal, Torgeir ;
Aass, Nina ;
Dahl, Olav ;
Klepp, Olbjorn ;
Langberg, Carl W. ;
Wilsgaard, Tom ;
Bremnes, Roy M. ;
Fossa, Sophie D. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4649-4657
[10]  
Howlader N., 2011, SEER cancer statistics review, 1975-2008